WO2005078088A1 - Dnaなどの分離精製機構 - Google Patents
Dnaなどの分離精製機構 Download PDFInfo
- Publication number
- WO2005078088A1 WO2005078088A1 PCT/JP2004/001465 JP2004001465W WO2005078088A1 WO 2005078088 A1 WO2005078088 A1 WO 2005078088A1 JP 2004001465 W JP2004001465 W JP 2004001465W WO 2005078088 A1 WO2005078088 A1 WO 2005078088A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- buffer
- purification
- monolith
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
Definitions
- the present invention relates to a mechanism for separating and purifying DNA and the like.
- nucleic acid-containing substances include biological fluids such as cultured cells, tissues, blood, serum, urine, and feces, bacteria such as bacteria and Mycobacterium tuberculosis, and HIV ⁇ biological materials such as viruses such as hepatitis B and C. It is mainly a substance, and plasmid DNA, genomic DNA, chromosomal DNA, RNA, mitochondrial DNA, fragment DNA, etc. can be separated and purified.
- the purification efficiency can be considered to be equal to the efficiency of contact between the carrier surface and the biological sample.
- the carrier to be adsorbed is held in a container (cartridge, chip, etc.), the biological sample is passed through the container, and the nucleic acid is adsorbed on the carrier with an adsorption buffer solution. It is common to use a washing solution to drive out contaminants other than nucleic acid components out of the cartridge, and then pass the eluate to remove nucleic acid components together with the solution.
- the beads are made smaller and the amount is increased in order to increase the contact efficiency between the surface and the nucleic acid.
- the pressure at the time of passing the liquid increases, and the operability is remarkably reduced.
- the space between beads is reduced, and the nucleic acid molecule has a large molecular weight.
- the pressure is increased and the amount of the eluted solvent is also increased, and the concentration efficiency is reduced.
- beads or wool is used, a small amount of the particles or particles enter the eluate, which is a problem for later applications.
- the filling method when filling the container is uncertain, the separation time and the pattern will change, so that there is a problem that the stability of the separation is poor.
- the method of using a membrane or a filter as a carrier is easy to use;!: The merit that can be obtained has a certain force S, it is difficult to control the pores suitable for separation, and it is not practical.
- the method of using a polymer requires a specific reaction with nucleic acid depending on the nature of the polymer, and the separation system becomes complicated due to the presence of a portion that has an effect other than the portion. The spirit of simple protocols Production is impossible.
- a nucleic acid mixture is prepared from an aqueous solution containing a high concentration of salt (ionic strength) and containing an organic acid such as aliphatic alcohol or polyethylene daricol, or a porous or non-porous inorganic substrate such as gel or glass.
- a method for obtaining a nucleic acid by adsorbing on the top, washing, and then eluting with a solution containing a lower concentration of salt (ionic strength) has been proposed in Japanese Patent Application Laid-Open No. 8-501131.
- a nucleic acid mixture is adsorbed on an inorganic substance from an aqueous solution containing a high concentration of salt, and nucleic acids are eluted with a solution containing a low concentration of salt, for example, DNA.
- a solution containing a low concentration of salt for example, DNA.
- the sample is contained in a large piece of agarose, it must be processed using multiple columns, the eluted fragment DNA is pooled, and the resulting fragment DNA contains salts and organic solvents. And desalting and other operation steps are required, and the purified DNA may be lost during ethanol precipitation. Disclosure of the invention
- the above-mentioned points of the prior art are improved, and adsorption and elution and separation can be performed extremely easily and easily, and elution with a high concentration of salt is not performed.
- it aims to propose a highly reproducible method in which the separation and purification of fragment DNA and the like is remarkably efficient. It is an integrated Molinos structure that has a continuous through hole from one end to the other end, and a through hole corresponding to a nucleic acid size of 35 bp (mer) and lOOK bp (mer).
- the monolith structure is characterized in that the solution containing the nucleic acid to be separated is passed so that the nucleic acid corresponding to each of the through holes can be retained, and the monolith structure is made of an inorganic material such as glass, silica, or the like. It is a hybrid body containing organic matter in the machine, characterized by using a porous body having a macropore passing through from the upper surface to the lower surface.
- the porous body of the monolithic structure is a macro body. It is characterized by having micropores inside the pores, and the porous body of the monolithic structure has macropores of 1 to 100 ⁇ m and micropores of 0 to 100 nm.
- the monolithic solid-phase column is formed by detachably mounting a base composed of a monolithic structure on a cylindrical body that is open up and down. Is used.
- nucleic acid adsorption and separation can be performed without using sensitive reaction conditions, so that dissolution and adsorption with a high concentration of salt are not required, and concentration and desalting operations are not required.
- it can be dissolved in a salt-free solution or sterile water, and a highly purified fragment DNA or the like can be easily obtained.
- FIG. 1 is a comparison diagram of the first embodiment of the present invention with the conventional method
- FIG. 2 is a comparison diagram of the first embodiment of the present invention with the conventional method
- FIG. 3 is a diagram of the first embodiment of the present invention.
- FIG. 4 is an evaluation chart by HP LC.
- FIG. 5 is a DNA fragment purification separation diagram
- FIG. 5 is a DNA fragment purification separation diagram of Example 4 according to the present invention
- FIG. 6 is a DNA fragment purification separation diagram of Example 5 according to the present invention
- FIG. FIG. 8 is a separation diagram of a single-stranded PCR amplification product of Example 6 according to the present invention
- FIG. 8 is a comparison diagram of purification with sodium and potassium of Example 7 according to the present invention
- FIG. 10 is a slant diagram for disk explanation as above
- Fig. 11 is a slant diagram for collection tube same as above
- Fig. 12 is a slope for monolith solid phase column as above.
- the present inventors have found that, when an efficient monolith structure is used for nucleic acid purification and buffer conditions are adjusted, it is not necessary to use a buffer having a high salt concentration, which has been widely accepted. I found it.
- Tris-HCl EDTA which is added for storing nucleic acids
- only water dissolves and dissolves from the adsorbed carrier.
- chloride is used as a solvent to supply ions that are thought to react with isopropanol and silanol groups, which act as a separation solvent
- guanidine hydrochloride a chaotropic salt for dissolving agarose gel, is used as the adsorption solvent. .
- an alkali metal salt which is likely to become a cation, easily causes a dehydrogenation reaction, whereby the cation causes a cationic cross-linking reaction with the phosphate moiety of the nucleic acid, and is considered to adsorb the nucleic acid.
- the alkali metal include lithium, sodium, potassium, rubidium, cesium, and francium.
- potassium salts which have low electronegativity, easily become cations, and undergo a cationic cross-linking reaction, are liable to react. It is useful because it does not. It should be noted that sodium salts will interfere with subsequent applications. Therefore, it cannot be used without desalting operation and is not very useful.
- this apparatus and method does not require desalting or alcohol precipitation, and allows the obtained purified solution to be directly used in subsequent operations (PCR, cloning, sequencing, enzymatic operations). become. Simplification of the operating procedure is very important to prevent nucleic acid damage.
- An object of the present invention is to use a monolithic structure having a high purification efficiency or a glass and use a simpler buffer so as not to affect the subsequent operation of various applications such as clawing, and to remove nucleic acids. It is to provide a method that can be purified.
- the monolith structure refers to an integrated porous body having an open macropore that communicates from the upper end to the lower end, and many macropores with macropores are synthesized. .
- the monolith structure can be mainly produced by a sol-gel method. That is, the metal alkoxide is partially hydrolyzed to form a reactive monomer, and the monomer is polycondensed to form a colloidal oligomer (formation of a sol), which is further hydrolyzed to promote polymerization and crosslinking, It is synthesized by creating a three-dimensional structure (generating a gel).
- an organic / inorganic hybrid monolith can be easily prepared. Therefore, chemical characteristics can be added depending on the type of the organic monomer to be added. For example, by adding an organic monomer having a hydrophilic group, the water absorption of the aqueous sample component can be improved. In addition, by adding an organic monomer having a functional group that exhibits selective chemical action, it can be used for adsorption of characteristic components that become impurities in purification, and the impurities can be left in the solid phase to improve nucleic acid purification efficiency. You will be able to upgrade. In addition, by introducing a polymer with a high modulus of elasticity into the sol-gel process, the monolith structure can be made elastic. Can also be. Basically, by mixing organic and inorganic materials, it becomes possible to increase the chemical stability of the monolith structure.
- the organic / inorganic hybrid monolith structure produced by the sol-gel method can be used to construct a chemical surface according to the purpose with the type of organic monomer added, or to improve the chemical stability.
- the monolithic properties that are effective in DNA pretreatment can be freely improved according to the purpose.
- the monolith prepared by the sol-gel method is suitable as the solid phase for DNA of the present invention because of its low metal content.
- General silica gel is made from sodium silicate, etc., leaving a large amount of metal.
- some are made from purified sodium silicate and some are high-purity siligels from the sol-gel method, but they are expensive and are not suitable for disposable, which is the usual mode of use .
- it is a batch synthesis at the time of particle preparation and there is a high possibility that metal concentration will occur from the synthesis atmosphere.
- silica gel has been devised by washing with hydrochloric acid, nitric acid, or the like, and addition of EDTA or the like to reduce the influence of metal has not been required in the solid phase of the present invention.
- a monolithic solid phase can be created by glass phase separation. Basically, it has the same effectiveness as the synthesis of the monolith structure from the sol-gel method, but since the macropore can be made larger than the sol-gel monolith, the secondary micropores are formed on the inner surface. It is effective when making it. Furthermore, there is an advantage that glass phase separation has higher alkali resistance than its composition and can be regenerated by alkali washing.
- fragment DNA is For purification from DNA gels, single-stranded DNAs and RNAs, etc., in the presence of chaotropic salts, it is adsorbed on glass or silica for purification from DNA gels, PCR products, restriction enzyme-treated DNA, RNA, etc.
- a monolith structure formed by the above that is, an integrated porous body having an open structure in which pores communicate from the upper end to the lower end is used and adsorbed on the monolithic structure.
- the present invention has a part in common with the prior art in that a substance adsorbed on glass or silica gel particles is extracted from an agarose gel or a PCR reaction solution in the presence of a chaotropic salt.
- This conventional technique quantitatively causes adsorption in the presence of a high concentration of a kato-mouth pick salt, and elution of the adsorbed nucleic acid is performed at a lower salt concentration.
- the method disclosed in Japanese Patent Application Laid-Open No. 8-501131 is a method in which nucleic acids to be separated are subjected to nucleic acid fractionation in one operation step without a preliminary purification step.
- This requires extreme reaction conditions with a high concentration of salt buffer, and narrows the applicable molecular weight range of nucleic acids.
- purified DNA is extremely dilute and contains salts and organic solvents, so it is necessary to further precipitate or concentrate ethanol.
- the present invention improves on these drawbacks and does not adsorb or elute at high concentrations of salt but elutes with water. This results in very high concentrations and further A sample that does not require purification is obtained.
- An object of the present invention is to purify a DNA fragment from an agarose gel, a PCR amplification reaction DNA solution, a fragment DNA from an enzyme reaction solution, and the like.
- the present invention relates to DNAs of 3513 1) to 1001 ⁇ 31) from a standard agarose gel or a low-boiling agarose gel prepared with a Tris acetate (TAE) buffer or a Tr.is borate (TBE) buffer. Extraction and purification of the fragments are possible, and a recovery of 60 to 80% can be obtained.
- the PCR product of 35 bp ⁇ : LOOKbp can also be directly purified from the PCR amplification reaction solution, and a recovery of 80 to 95% can be obtained. Since the obtained fragment DNA does not contain salts or organic solvents, there is no need for ethanol precipitation, desalting or concentration.
- the product is a monolith-based system with a maximum DNA binding capacity of 5-8 ⁇ g, and can recover isolated fragment DNA in as little as 5 minutes.
- a buffer (dissolution, adsorption buffer)
- A1 buffer for PCR reaction solution (guanidine hydrochloride 1-8 M, potassium acetate 0.1-: less than LM, 2-propanol 1-70%)
- A2 buffer for agarose gel (1-8 M guanosine thiocyanate, less than 0.1-1 M potassium acetate, 2-propanol 1-70%)
- B buffer 0.1-1 M less potassium acetate
- Ethanore 1 ⁇ 80%
- guanidine hydrochloride is preferably guanidine thiocyanate, more preferably 1 to 8M. More than 40% of 2-propanol is efficient.
- the elution buffer solution C can be eluted with water, but RNase-free water treated with an ultrafiltration membrane or treated with diethylpyrocarbonate to prevent contamination by various bacteria It is recommended to use When storing the purified DNA, water to which EDTA buffer has been added in advance may be used as elution buffer solution C in order to prevent bacterial contamination. From the viewpoint of the separation mechanism, the purification efficiency does not change depending on the presence or absence of the EDTA buffer.
- the reaction between the phosphoric acid group of the nucleic acid and the silanol group can be efficiently advanced by using the monolith structure for the substrate.
- the sample is purified while silica particles adhere to an inevitable sample, thereby preventing a problem of silica carryover that may hinder a so-called application reaction.
- the pressure at the time of separation can be kept low, and unlike using filler, sealing It has advantages such as no need for a stopper.
- This monolithic structure can be produced by, for example, a so-called sol-gel method in which an inorganic porous material such as silica gel is purified from a polymerizable low-molecular compound sol to finally obtain an aggregate or polymer gel. I can do it.
- This method generally has a central pore diameter of 1 to 100; um, but several nm can be achieved due to subsequent technological advances.
- a monolith structure in which pores are present in a silicic skeleton having two types of pores can be created by utilizing spinor-dal decomposition in the sol-gel process.
- a porous body having a structure in which a porous body having micropores having an open structure is filled inside macropores penetrating from the upper surface to the lower surface can be produced.
- this porous body has a macropore diameter of 1 to 100 m and a micropore of 0 to LOOnm.
- the through-holes of the porous body can be formed as desired by the manufacturing method. Therefore, the through-holes are appropriately selected and formed, but a thickness of about 1 to 100 m is easy to use. However, this choice is determined by the raw materials used, eg, agarose gel-PCR reaction, buffer, and for its purpose.
- a cylindrical column tube 1 is formed, and a sealable lid 3 is detachably provided at an upper end open portion 2.
- An outlet 4 having a small diameter is formed at the lower end, and a step 5 is provided at an upper portion of the outlet 4 to form a medium diameter portion 6.
- a disc 7 as a substrate formed of a monolithic structure can be placed or fitted on the step 5.
- the disk 7 has substantially the same shape as the medium-diameter portion 6 and has a desired thickness, for example, a disk shape of about 0.1 to 1 Omm or a conical shape if desired. Good.
- the column tube 1 and the disk 7 constitute a monolithic solid phase column 9.
- Reference numeral 8 denotes a collection tube having a diameter that allows passage of the column tube 1 and an upper end edge of the column tube 1 that can be locked at an upper portion.
- Polypropylene is used for the column tube 1 and the collection tube 8, but organic polymers that do not affect nucleic acids, such as polyethylene, polyethylene terephthalate, polystyrene, and inorganic compounds such as glass and silica are used. Can be used if it has good strength.
- the disk 7 is mentioned as a base of the monolith structure, the present invention is not limited to this, and it can be used in a dish-shaped or cylindrical-shaped mold through which a solution can freely pass.
- the molecular size of DNA is said to be about 3.4 nm per 10 base pairs.
- macropores of ⁇ 10 / m, 30 Kbp3O ⁇ Kbp DNA It is thought that a DNA molecule with a pore size of about 100 / im can pass through DNA molecules without damaging or soiling the DNA molecules.
- micropores are added. Based on experience in various tests and experiments, if the micropore is around 10 nm, there is an interaction with a compound with a molecular weight of 100,000, and if the micropore is around 10 nm, there is an interaction with a compound with a molecular weight of hundreds to tens of thousands. It has been confirmed that, for a compound having a higher molecular weight, a state in which micropores, which promote the destruction of the molecule, are infinite, that is, 0 nm is preferable.
- a monolith structure having a macropore of 1 to 100 ⁇ m, preferably about 20 ⁇ m and a micropore of 0 to 100 nm, preferably about 10 nm is used. Purification of a wide range of DNAs from 35 bp (mer) to LOOK bp (mer), as in Examples, is sufficiently possible.
- This protocol is designed for the purpose of purifying double-stranded DNA fragments from a PCR reaction solution. If one monolithic solid-phase column and a purification buffer are used, centrifugation can be performed to obtain 35 bp to: LOOK bp. Fragments can be separated from primers, nucleotides, polymerases, salts and the like.
- buffer A1 adsorption buffer
- wash buffer B with about 300 ⁇ l (wash buffer).
- the monolithic solid phase column can be operated with a suction manifold including a general luer adapter. This protocol has been designed to purify double-stranded DNA fragments from PCR reactions. If one monolithic solid phase column and a purification buffer are used, the fragmentation of 35 bp to: LOOK bp can be separated from primers, nucleotides, polymerases, salts, and the like by a sample processing operation using a suction device.
- buffer A1 adsorption buffer
- wash buffer B with about 300 ⁇ l (wash buffer).
- the sample solution to the monolithic solid phase column 9 without leaving it.
- the maximum volume to be added is 8001 and the sample volume is 800 ⁇ l. If the amount is large, add in several portions.
- Centrifugation is required to completely remove the residual ethanol from the buffer. (Suction and dry until the liquid has passed through the monolithic solid phase column. This is a necessary means to completely remove the washing buffer remaining in the monolithic solid phase column 9.)
- the elution efficiency is maximum when ⁇ 8 is between 8 and 8.5. When using a sterile water system for elution, it is advisable to confirm that ⁇ ⁇ ⁇ is within this range.
- This protocol is designed for the purification of D ⁇ fragments from standard or low-melting agarose gels ( ⁇ or ⁇ ⁇ ⁇ buffer), and using a single monolith column and purification buffer.
- 3 5 b! To 10 OK bp fragments can be separated from primers, nucleotides, polymerases, salts and the like.
- a single monolith column can process up to 100 mg of agarose. Add 10 ⁇ l of Buffer ⁇ (dissolution, adsorption buffer) to 1 mg of agarose gel. Wash buffer B with about 5001 (wash buffer).
- the monolith column can be operated by a suction manifold including a luer adapter. This protocol was designed to purify DNA fragments from standard or low-melting agarose gels (using TE or TBE buffer). If one monolithic column and a purification buffer are used, a fragment of 35 bp to 10 OK bp can be separated from primers, nucleotides, polymerases, salts, etc. by a sample processing operation using a suction device.
- Elution is performed by centrifugation at ⁇ 10,000 rpm in a tabletop microphone-mouth centrifuge.
- the following methods can be used to purify the enzyme reaction mixture using a monolithic solid phase column.
- This protocol was designed to purify double-stranded DNA fragments from enzyme reactions such as restriction enzyme digestion and labeling reactions. If one monolith column and a purification buffer are used, a fragment of 35 bp to 10OKb: can be separated from enzymes, primers, nucleotides, salts, and the like by centrifugation.
- wash buffer ⁇ with approx. 301 (wash buffer).
- the monolith column is connected to a suction manifold including a luer adapter. More operations can be performed. This protocol was designed for the purpose of purifying a double-stranded DNA fragment from an enzyme reaction solution such as a restriction enzyme digestion-labeling reaction. If one monolithic column and a purification buffer are used, a fragment of 35 bp to 35 Kbp can be separated from enzymes, primers, nucleotides, salts, etc. by a sample processor using a suction device.
- buffer A1 adsorption buffer
- wash the buffer with about 300 ⁇ l (one washing buffer).
- silica gel particles, glass particles, and those obtained by filtering them are used. In all of them, the space through which the liquid passes will pass through the particle surface, and will hit the particles, causing turbulence and an uneven flow. Therefore, touching all surfaces uniformly Can not.
- the monolith structure has an integral structure and continuous holes inside, so the image passes through the inside of the particle. That is, all the liquids come into uniform contact.
- the skeleton is small, and the flow is uniform without turbulence after the liquid is hit.
- the reaction is easily caused by increasing the chaotropic salt concentration in order to prevent the escape.
- salt precipitation occurs and limits are imposed, so that the collection of small molecule DNA is limited.
- the monolith type of the present invention a uniform liquid flow is ensured, and adsorption of lower-molecular-weight DNA becomes possible.
- an inorganic base material is disposed near an outlet of a cylindrical hollow body having an inlet and an outlet, and the inorganic base material is sandwiched between tightly packed polyethylene frit. There are examples that are retained. (Patent Document 3)
- the portion contributing to the separation is the inorganic base material portion, and the upper and lower frit are used to hold the inorganic body in a hollow body. No matter how tight it is, a space will be created between the frit and the inorganic material, and the liquid will remain in that space. Liquid in that space Expulsion and replacement becomes difficult.
- the depressurization method if a gas phase part is formed in a part, the part flows preferentially, and the liquid cannot be drained uniformly. In the sample addition and washing steps, replacement of the liquid becomes difficult.
- the pores of the orifice through which the liquid flows become a continuous body, and the liquid changes uniformly in the direction of flow. That is, the displacement efficiency of the liquid greatly increases.
- this conventional type is considered to be one of the causes of a large amount of sample components remaining after the second elution.
- the monolith structure of the continuum according to the present invention it can be seen that, since the displacement efficiency of the liquid is high, one elution is sufficient, and the second dissolution hardly remains.
- the monolithic structure is an integral structure, and there is no variation when the monolithic structure is pushed into the hollow body.
- it is expensive as a commercial product and does not exist, it is also possible to further crush the frit and the inorganic material into one, but this method also creates a different layer at the crushed interface. Liquid flow is impeded compared to monolith structures, which also have uniform continuous holes.
- an inorganic substance such as silica gel and an organic substance such as polyethylene as a frit material are mixed in the sol-gel process, it is possible to prepare a uniform phase of a hybrid having the properties of silica and polyethylene. It is. If the inorganic material is in the form of particles, the upper and lower flits are indispensable to stop it, and the problem of replacement efficiency as described above arises.
- Silica gel film with silica fiber ⁇ kel particles embedded for example, 3M company Even if Mporeadisk (registered trademark) is used as an inorganic material, it still has no physical hardness, and may be deformed due to rapid decompression or high-speed centrifugation, and some of the fibers and particles may be eluted. is there. Even with a slight deformation, the volume of space will change, which will be a factor of variation. In the monolithic structure, reproducibility can be obtained because it is not deformed even by pressure fluctuations because it is separated by continuous pores inside a rigid skeleton.
- Mporeadisk registered trademark
- a monolithic structure that does not generate turbulence can achieve adsorption of low-molecular-weight DNA and high cleaning effect.
- the channels of the conventional type particles and the micropores in the monolith structure of the present invention are different in that they are in contact with the liquid flow.
- particle type there is no uniformity of pressure in the liquid resistance between the side where liquid enters and the side where liquid exits, and the contact of the liquid inside the pores differs.
- HPLC pressurized system
- the pressure can be made uniform, so the effect is reduced.
- the inlet side is at normal pressure
- the outlet side is under negative pressure, and particles Ingress and egress into and out of the pores in one piece becomes uneven.
- the same component may or may not enter the pores depending on the component molecules, and the width at the time of elution will increase in total. Therefore, it is difficult to remove only the components to be removed at the time of washing, and the finally eluted components remain in the low molecular side primer as in the conventional example shown in Example 1.
- the micropores are present on the surface of the macropores through which the liquid flows, so that all of them enter uniformly. Therefore, it is possible to easily remove the primer which is a low molecular impurity.
- the conventional method for large DNA, it is difficult to get into the small holes, and the viscosity of the liquid containing the components also increases, so that the contact becomes uneven and two phenomena occur simultaneously. It is considered that many parts are not adsorbed. The turbulence also causes physical damage to the high molecular weight DNA, increasing the possibility of rupture.
- the salt concentration can be reduced, and the above problems can be solved, which is very effective.
- it is more effective to use a combination of a permeate with a cation exchange action.
- Potassium salt has a strong cation exchange effect and contributes to the adsorption of nucleic acids to the surface.However, if it remains on the substrate surface during elution, the problem arises that the target purified DNA will not elute. However, reliable cleaning is indeterminate. In the case of the particle type, turbulence is generated even during washing, and the penetration into the pores is uneven, so that a portion where the potassium salt remains in the substrate at a high concentration is inevitably formed.
- a buffer that can remove potassium, that is, other salts may be added to the eluate, but this is still not suitable for the purpose of later application. '
- the potassium salt works effectively because a uniform flow of the liquid and a uniform penetration into the pores are possible. .
- Example 1 For purification of a PCR reaction solution (fragment DNA), pCR amplification reaction product 50/1 was mixed with buffer A 1 (1 M guanidine hydrochloride, 0.2 M potassium acetate, 50% 2-propanol). ) Mix to 300 / zl. Insert the silica monolith solid phase column 9 into the collection tube 8, inject the mixture into the silica monolith solid phase column 9, and centrifuge in a 1.5 ml centrifuge tube. Wash the silica monolith solid phase column 9 with B buffer (0.2 M potassium acetate, 50% ethanol) to remove salts.
- buffer A 1 1 M guanidine hydrochloride, 0.2 M potassium acetate, 50% 2-propanol
- elution buffer C EDTA 4 mM, Tris — HCI 1 OmM, pH 8 or sterile DNA, RNA free water
- elution buffer C EDTA 4 mM, Tris — HCI 1 OmM, pH 8 or sterile DNA, RNA free water
- (1) is an evaluation by electrophoresis of a sample (400 bp) purified by the conventional method of Patent Document 3.
- 2 is the method of the present invention.
- (1) a large amount of the lower (lower) portion remains, but in (2), almost no residue remains, and high purification efficiency is obtained.
- 11 and 1 and 2 are performed by the conventional method twice and the remaining is observed, and 2 and 1 and 2 are those of the present invention. In the case of the present invention, it hardly remains in the first run, indicating that high purification efficiency can be obtained.
- Figure 3 shows the evaluation using HPLC.
- HPLC conditions are as follows HPLC conditions
- a / B 50 / 50- (10MIN) -0/100 Flow rate: 3ral / min
- the HPLC evaluation data of the unpurified PCR solution is the top chromatogram, which shows a change in the pattern as compared to the conventional Kokuto Mataram (bottom) purified by the method of Patent Document 3.
- dNTPS and the primer were hardly excluded.
- the two peaks of dNTPS and the primer were significantly removed as in the second method, indicating that the target nucleic acid was highly purified.
- Example 2 In the purification of DNA fragments from agarose gel, the PCR amplified product was electrophoresed on a standard or low-melting-point agarose gel (using TE or TBE buffer), and the DNA was converted to agarose gel. Or in 8 £ 0.5%). Cut the DNA fragment to be isolated with a clean force razor or scalpel from the gel and place it in a 1.5 ml centrifuge tube. Mix in Buffer A 2 (2 M guadindinocyanic acid, 0.4 M potassium acetate, 30% 2-propanol) at 300/1 and dissolve gel slice completely at 60 ° C for 5 minutes. Incubate until done.
- Buffer A 2 (2 M guadindinocyanic acid, 0.4 M potassium acetate, 30% 2-propanol
- the lysate was introduced into the monolithic solid phase column 9 according to Example 1, and the mixture was injected into the monolithic solid phase column 9 in a 1.5 ml centrifuge tube. Centrifuge. Treat monolithic solid phase column 9 with buffer B (0.2 M potassium acetate, 50% ethanol) ⁇ : Wash more to avoid salt.
- buffer B 0.2 M potassium acetate, 50% ethanol
- small molecules from 35 bp to about lOOK bp are recovered. This indicates that a wide range of DNA can be purified from agarose gel. Similar results were obtained with water containing no EDTA buffer as the elution buffer.
- Example 3 DNA 100 ⁇ g after restriction enzyme reaction is treated with a restriction enzyme. This DNA restriction reaction solution was mixed with buffer A1, 300 ⁇ l according to Example 1, and the subsequent processing was performed in the same manner as in Example 1. After elution, the obtained purified DNA did not contain restriction enzymes and salts, and the ratio of absorbance measurement (mm) 260 Z280 was as good as 1.8.
- Example 4 For purification of a 35 bp PCR product with a small molecular size, PCR amplification reaction product 101 was mixed with buffer A1, 100 ⁇ l according to Example 1, and the subsequent processing was performed. Was performed in the same manner as in Example 1. (See Fig. 5) ⁇ : molecular weight marker, 1: sample before purification, 2: sample purified by the present invention.
- Example 5 For purification of a PCR amplification product having a large molecular size (from 100 bp to 100,000 bp), use PCR amplification reaction solution (20 ⁇ l) according to Example 1 in buffers A1, 2 0 0 / ⁇ 1, and the subsequent processing was performed in the same manner as in Example 1. (See Fig. 6) In the figure, ⁇ ⁇ ⁇ ⁇ : molecular weight marker, 1: sample before purification, 2: sample purified by the present invention, 3: sample purified by conventional method.
- Example 6 In the purification of a single-stranded DNA solution, 20 ⁇ l of the solution was mixed with buffers A 1 and 201 according to Example 1, and the subsequent treatment was performed in the same manner as in Example 1. (See Fig. 7) M: molecular weight marker, 1: purification Previous sample, 2: sample purified according to the present invention.
- the single-stranded DNA 35 m er was not recovered by the conventional method (3) Force S, and in the present invention (2) It was recovered both times with good reproducibility.
- DNA separation and purification characterized by adsorbing the corresponding nucleic acids to the through-holes of the monolithic monolith structure by intercalating the solution containing nucleic acids with metal salts, washing with a washing solution, and then eluting.
- a method for separating and purifying DNA wherein the alkali metal salt is potassium acetate.
- a method for separation and purification comprising using a dissolution and adsorption buffer containing 0.1 to less than 1 M of potassium acetate.
- a method for separating and purifying DNA wherein dissolution and adsorption are carried out using a dissolution / adsorption buffer containing a guanidine salt or a potassium sulfate such as acetic acid potassium.
- Tris A method for separating and purifying DNA, characterized by elution with water containing HCl and EDTA.
- Dissolution, adsorption, separation, and washing operations are performed using a single monolithic solid phase column.
- a method for separating and purifying DNA is performed using a single monolithic solid phase column.
- Kit consisting of dissolution and adsorption buffer, water and separation and purification mechanism.
- the separation and production mechanism of DNA and the like according to the present invention is very frequently used in molecular biology research, and is used for PCR, cloning, sequence sink, restriction enzyme digestion, and other enzyme actions. Particularly useful for purification of fragment DNA, etc., performed prior to application.Quantitative separation and efficient purification of a wide range of DNA of 35 bp (mer) and less than 100 Kbp (mer). Can be used to purify a wide range of nucleic acids.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04710506A EP1719816B1 (en) | 2004-02-12 | 2004-02-12 | Mechanism of separating and purifying dna |
JP2005517842A JP4597870B2 (ja) | 2004-02-12 | 2004-02-12 | Dnaなどの分離精製機構 |
US10/597,954 US8586350B2 (en) | 2004-02-12 | 2004-02-12 | Mechanism of separating and purifying DNA and the like |
PCT/JP2004/001465 WO2005078088A1 (ja) | 2004-02-12 | 2004-02-12 | Dnaなどの分離精製機構 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2004/001465 WO2005078088A1 (ja) | 2004-02-12 | 2004-02-12 | Dnaなどの分離精製機構 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005078088A1 true WO2005078088A1 (ja) | 2005-08-25 |
Family
ID=34857513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/001465 WO2005078088A1 (ja) | 2004-02-12 | 2004-02-12 | Dnaなどの分離精製機構 |
Country Status (4)
Country | Link |
---|---|
US (1) | US8586350B2 (ja) |
EP (1) | EP1719816B1 (ja) |
JP (1) | JP4597870B2 (ja) |
WO (1) | WO2005078088A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009150834A1 (ja) | 2008-06-12 | 2009-12-17 | 住友ベークライト株式会社 | 糖鎖試料調製方法、糖鎖試料および糖鎖分析法 |
JP2011502251A (ja) * | 2007-10-31 | 2011-01-20 | アコーニ バイオシステムズ | サンプル調製装置 |
WO2011158815A1 (ja) * | 2010-06-18 | 2011-12-22 | 東洋紡績株式会社 | 抗酸菌の溶菌とその核酸の分離を同時に行う方法 |
JP2013533741A (ja) * | 2011-05-16 | 2013-08-29 | ナノヘリックス カンパニー リミテッド | 超高速核酸精製方法 |
JP5570422B2 (ja) * | 2009-01-16 | 2014-08-13 | アークレイ株式会社 | 核酸試料の製造方法、および、それを用いた核酸増幅物の製造方法 |
JP2015526091A (ja) * | 2012-08-28 | 2015-09-10 | バイオキューブシステム カンパニーリミテッドBio Cube System Co., Ltd. | 生物学的試料から核酸増幅反応用生物学的分子を迅速に分離するための多孔性固体相及びその用途 |
WO2017119503A1 (ja) * | 2016-01-08 | 2017-07-13 | 株式会社ジーンデザイン | ゾル-ゲル法で作製される無機多孔質体を用いた核酸合成用担体 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0818609D0 (en) * | 2008-10-10 | 2008-11-19 | Univ Hull | apparatus and method |
JP2013522578A (ja) * | 2010-01-21 | 2013-06-13 | プロメガ コーポレイション | 高溶解性のプラスチックを含む消耗性の分析用プラスチック製品 |
AU2013330344B2 (en) | 2012-09-17 | 2018-07-05 | W. R. Grace & Co.-Conn. | Chromatography media and devices |
ES2730737T3 (es) | 2012-09-17 | 2019-11-12 | Grace W R & Co | Material de soporte de partículas funcionalizado y métodos de fabricación y uso del mismo |
ES2887110T3 (es) | 2014-01-16 | 2021-12-21 | Grace W R & Co | Medios para cromatografía de afinidad y dispositivos para cromatografía |
EP3099799B1 (en) | 2014-01-28 | 2019-05-15 | Dice Molecules SV. LLC | Arrays of monoliths with attached recognition compounds |
JP6914189B2 (ja) | 2014-05-02 | 2021-08-04 | ダブリュー・アール・グレース・アンド・カンパニー−コーンW R Grace & Co−Conn | 官能化担体材料並びに官能化担体材料を作製及び使用する方法 |
EP3302784B1 (en) | 2015-06-05 | 2021-10-06 | W.R. Grace & Co.-Conn. | Adsorbent bioprocessing clarification agents and methods of making and using the same |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59227744A (ja) | 1983-06-08 | 1984-12-21 | Rikaken Kk | Dna回収用ガラス粉粒物 |
NL8900725A (nl) | 1989-03-23 | 1990-10-16 | Az Univ Amsterdam | Werkwijze en combinatie van middelen voor het isoleren van nucleinezuur. |
DE4321904B4 (de) | 1993-07-01 | 2013-05-16 | Qiagen Gmbh | Verfahren zur chromatographischen Reinigung und Trennung von Nucleinsäuregemischen |
DE69922740T2 (de) * | 1998-05-11 | 2005-12-08 | Tosoh Corp., Shinnanyo | Methode zur Trennung von Nucleinsäuren mittels Flüssigchromatographie |
EP0969090A1 (en) * | 1998-05-27 | 2000-01-05 | QIAGEN GmbH | Rapid and simple process for isolation of circular nucleic acids |
US6238565B1 (en) | 1998-09-16 | 2001-05-29 | Varian, Inc. | Monolithic matrix for separating bio-organic molecules |
DE19903507A1 (de) * | 1999-01-29 | 2000-08-10 | Roche Diagnostics Gmbh | Verfahren zur Herstellung endotoxinfreier oder an Endotoxin abgereicherter Nukleinsäuren und deren Verwendung |
JP2003532088A (ja) | 2000-05-01 | 2003-10-28 | トランスジエノミツク・インコーポレーテツド | ポリマー分離媒体でのポリヌクレオチド分離 |
JP2004532392A (ja) | 2001-02-20 | 2004-10-21 | アドヴィオン バイオサイエンシィズ インコーポレイテッド | 親和性吸着剤を有するマイクロチップ電子噴霧装置およびカラムならびにそれらの使用法 |
JP3644426B2 (ja) | 2001-11-15 | 2005-04-27 | 株式会社日立製作所 | 核酸の精製分離方法および装置 |
US20040002081A1 (en) * | 2001-12-18 | 2004-01-01 | Boehringer Ingelheim International Gmbh And Bia Separations D.O.O. | Method and device for isolating and purifying a polynucleotide of interest on a manufacturing scale |
US20030148291A1 (en) * | 2002-02-05 | 2003-08-07 | Karla Robotti | Method of immobilizing biologically active molecules for assay purposes in a microfluidic format |
JP4220164B2 (ja) | 2002-02-06 | 2009-02-04 | 東洋紡績株式会社 | 核酸の精製方法および当該方法に用いる核酸抽出用溶液ならびに核酸精製用試薬キット |
-
2004
- 2004-02-12 WO PCT/JP2004/001465 patent/WO2005078088A1/ja active Application Filing
- 2004-02-12 JP JP2005517842A patent/JP4597870B2/ja not_active Expired - Lifetime
- 2004-02-12 EP EP04710506A patent/EP1719816B1/en not_active Expired - Lifetime
- 2004-02-12 US US10/597,954 patent/US8586350B2/en active Active
Non-Patent Citations (3)
Title |
---|
ALES PODGORNIK, ET AL: "Application of very short monolithic columns for separation of low and high molecular mass substances", JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, vol. 25, no. 20, 2002, pages 3099 - 3116, XP002976459 * |
LUBBAD S, ET AL: "Micropreparative fractionation of DNA fragments on metathesis-based monoliths: influence of stoichiometry on separation", J CHROMATOGR A., vol. 959, no. 1-2, 2002, pages 121 - 129, XP004360281 * |
WALCHER W, ET AL: "Monolithic capillary columns for liquid chromatography-electrospray ionization mass spectrometry in proteomic and genomic research", J CHROMATOGR B ANALYT TECHNOL BIOMED LIFE SCI., vol. 782, no. 1-2, 2002, pages 111 - 125, XP004394220 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011502251A (ja) * | 2007-10-31 | 2011-01-20 | アコーニ バイオシステムズ | サンプル調製装置 |
WO2009150834A1 (ja) | 2008-06-12 | 2009-12-17 | 住友ベークライト株式会社 | 糖鎖試料調製方法、糖鎖試料および糖鎖分析法 |
JP5570422B2 (ja) * | 2009-01-16 | 2014-08-13 | アークレイ株式会社 | 核酸試料の製造方法、および、それを用いた核酸増幅物の製造方法 |
WO2011158815A1 (ja) * | 2010-06-18 | 2011-12-22 | 東洋紡績株式会社 | 抗酸菌の溶菌とその核酸の分離を同時に行う方法 |
JP2013533741A (ja) * | 2011-05-16 | 2013-08-29 | ナノヘリックス カンパニー リミテッド | 超高速核酸精製方法 |
JP2016010408A (ja) * | 2011-05-16 | 2016-01-21 | ナノヘリックス カンパニー リミテッド | 超高速核酸精製方法 |
JP2015526091A (ja) * | 2012-08-28 | 2015-09-10 | バイオキューブシステム カンパニーリミテッドBio Cube System Co., Ltd. | 生物学的試料から核酸増幅反応用生物学的分子を迅速に分離するための多孔性固体相及びその用途 |
US10837010B2 (en) | 2012-08-28 | 2020-11-17 | Bio Cube System Co., Ltd. | Porous solid phase for rapidly isolating biological molecules for nucleic acid amplification reaction from biological sample, and use thereof |
WO2017119503A1 (ja) * | 2016-01-08 | 2017-07-13 | 株式会社ジーンデザイン | ゾル-ゲル法で作製される無機多孔質体を用いた核酸合成用担体 |
JPWO2017119503A1 (ja) * | 2016-01-08 | 2018-10-25 | 株式会社ジーンデザイン | ゾル−ゲル法で作製される無機多孔質体を用いた核酸合成用担体 |
JP7033923B2 (ja) | 2016-01-08 | 2022-03-11 | 株式会社ジーンデザイン | ゾル-ゲル法で作製される無機多孔質体を用いた核酸合成用担体 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005078088A1 (ja) | 2007-08-30 |
EP1719816A4 (en) | 2007-06-06 |
JP4597870B2 (ja) | 2010-12-15 |
US8586350B2 (en) | 2013-11-19 |
EP1719816B1 (en) | 2011-06-01 |
EP1719816A1 (en) | 2006-11-08 |
US20070181482A1 (en) | 2007-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6383393B1 (en) | Chromatographic purification and separation process for mixtures of nucleic acids | |
JP5977921B2 (ja) | 核酸を精製することを目的とした装置、システムおよび方法 | |
EP1461155B1 (en) | Methods and devices for removal of organic molecules from biological mixtures using anion exchange | |
WO2005078088A1 (ja) | Dnaなどの分離精製機構 | |
KR0148693B1 (ko) | 핵산 분리방법 | |
US20120107799A1 (en) | Disposable, rapid extraction apparatus and methods | |
US20150166592A1 (en) | Selective Nucleic Acid Fragment Recovery | |
US20090215124A1 (en) | Nucleic acid isolation methods and materials and devices thereof | |
JP2009540868A (ja) | 生体分子を試料から単離するシステム | |
US8921539B2 (en) | Methods and devices for nucleic acid purification | |
JP2008529516A (ja) | エチレングリコール多量体の使用を含む核酸の単離方法 | |
US20160376636A1 (en) | Compositions and methods for sample preparation | |
JP2007244375A (ja) | リボ核酸の分離精製方法 | |
JP5880626B2 (ja) | 簡便かつ迅速な核酸抽出方法 | |
WO2016052386A1 (ja) | 核酸の分離精製方法および固相担体、デバイス、キット | |
JP4690656B2 (ja) | 核酸の分離精製方法及び分離吸着体 | |
US9434980B2 (en) | Method for concentrating sample constituents and for multiplying nucleic acids from a biological sample which are contained in the sample constituents | |
JP2010233579A (ja) | Dnaなどの分離精製機構 | |
KR101380909B1 (ko) | 핵산 정제용 흡착제 및 그 흡착제를 이용한 정제방법 | |
Mamaev et al. | Method for automated extraction and purification of nucleic acids and its implementation in microfluidic system | |
WO2021100801A1 (ja) | 核酸の分離方法、検出方法、核酸精製カラム及びその製造方法 | |
JP2010200661A (ja) | 簡便かつ迅速な核酸抽出方法 | |
RU2595374C2 (ru) | Способ автоматизированного выделения с одновременной очисткой нуклеиновых кислот из нескольких биологических образцов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005517842 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10597954 Country of ref document: US Ref document number: 2007181482 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004710506 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004710506 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10597954 Country of ref document: US |